文献速递银屑病与炎症性皮肤病

阿达木单抗治疗失败后抗IL-23与抗IL-17药物的疗效

Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-05-04

该回顾性研究分析1053例银屑病患者,比较抗IL-17和抗IL-23药物在阿达木单抗经治与生物制剂初治患者中的疗效。抗IL-17药物在两组间PASI100、PASI90和PASI<3无显著差异;抗IL-23药物在初治患者中起效更快,第16周PASI<3显著更高(77% vs 58%,p=0.048)。结论认为两类药物在初治或阿达木单抗失败后二线治疗中疗效无显著差异。

要点

  • 抗IL-17药物治疗后,阿达木单抗经治与生物制剂初治患者的PASI100、PASI90和PASI<3无显著差异。
  • 抗IL-23药物治疗后,生物制剂初治患者第16周PASI<3显著高于阿达木单抗经治患者(77% vs 58%,p=0.048)。
  • 多因素分析中,仅抗IL-17治疗对第52周PASI100有负向影响(OR 0.54,p=0.04),与既往治疗无关。

核心结论

  • 抗IL-23与抗IL-17药物在生物制剂初治患者中或作为生物类似药或原研阿达木单抗失败后的二线治疗,疗效无显著差异。

研究设计与样本

  • 回顾性分析1053例接受抗IL-17和抗IL-23药物治疗的银屑病患者,其中阿达木单抗经治者分别为68例和24例,生物制剂初治者分别为399例和260例。

主要发现

  • 抗IL-17治疗患者中,阿达木单抗经治与生物制剂初治患者的PASI100、PASI90和PASI<3无显著差异。
  • 抗IL-23治疗患者中,生物制剂初治患者起效更快,第16周PASI<3显著高于阿达木单抗经治患者(77% vs 58%,p=0.048)。
  • 在阿达木单抗经治且继发性失效的患者亚组中,抗IL-17与抗IL-23药物的疗效无显著差异。
  • 多因素分析显示,仅抗IL-17治疗对第52周PASI100有负向影响(OR 0.54,p=0.04),与既往治疗无关。
  • 对于PASI90,治疗类型和生物制剂初治状态在任何时间点均似乎无影响。

关键数值与推荐

  • 抗IL-23治疗第16周PASI<3:生物制剂初治患者77% vs 阿达木单抗经治患者58%(p=0.048)。
  • 第52周PASI100多因素分析:抗IL-17治疗OR 0.54(p=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many national guidelines at the European level recommend first-line therapy based on the anti-TNF-alpha adalimumab for treatment of psoriasis and psoriatic arthritis, mainly for economic reasons. Consequently, patients being treated with newer IL-17 and IL-23 inhibitors underwent previous unsuccessful first-line adalimumab-based therapy. OBJECTIVES: Evaluate the efficacy and safety of IL-17 and IL-23 inhibitors after treatment with adalimumab compared to adalimumab-naive psoriatic patients. METHODS: We retrospectively analysed 1053 psoriatic patients treated with anti-IL17 and anti-IL23 agents, which included 68 and 24 adalimumab-experienced and 399 and 260 bio-naive patients. Efficacy was assessed with mean PASI, PASI90, PASI100, and <3. RESULTS: Concerning the achieving of PASI100, PASI90 and PASI < 3 in patients treated with anti-IL17 agents, no significant differences were observed between adalimumab-experienced and bio-naive patients. In patients treated with an anti-IL-23 agent, a faster response was observed in bio-naive patients, with PASI < 3 significantly higher than ADA-experienced patients at 16 weeks (77% vs. 58% p = 0.048). In a sub-analysis that evaluated the performance of anti-IL17 and anti-IL23 agents in adalimumab-experienced patients with a history of secondary failure, no significant differences were found. In multivariate analysis of PASI100, only anti-IL-17 therapy appeared to have a negative impact at 52 weeks (OR: 0.54 p = 0.04) independently of previous treatment. For PASI90, type of treatment and bio-naïve status did not seem to have an impact at any time point. CONCLUSIONS: Anti-IL 23 and anti-IL 17 agents are not significantly different in terms of efficacy in bio-naive patients or as second-line therapy after failure with a biosimilar or originator adalimumab.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Mastorino L, Susca S, Cariti C, et al. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients. J Eur Acad Dermatol Venereol. 2023. PMID: 37113043. doi:10.1111/jdv.19135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。